Price movement over the last 24 hours
AdaptHealth Corp vs TJX Companies Inc — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while TJX Companies Inc trades at $153 (market cap $170.25B). The key difference: TJX Companies Inc is far larger — about 123.4× AdaptHealth Corp's market cap, and TJX Companies Inc pays a 1.25% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | TJX | |
|---|---|---|
Market Cap | $1.38B | $170.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $13.38 | $168.41 |
52-Week Low | $8.68 | $121.35 |
Enterprise Value | $3.33B | $178.85B |
Dividend Yield | — | 1.25% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
TJX trades at $154.11, up slightly by 0.02% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate, and maintains robust profitability with a 61.25% ROE. Revenue growth is steady, reaching $56.36B in 2025, supported by expansion in home goods and international markets.
Outlook remains positive with an 88% analyst buy rating and a $181.80 consensus price target, implying 18% upside. Risks include high valuation multiples like a 29.44 P/E and economic sensitivity, but strong cash flow and dividend payments provide stability. Investors should monitor Q2 2026 earnings for continued momentum.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →